MorphoSys AG
21.7.2021 22:22:12 CEST | ACCESS Newswire | Press release
PLANEGG, GERMANY and MUNICH, GERMANY / ACCESSWIRE / July 21, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR), a commercial-stage biopharmaceutical company and a leader in antibody and protein technologies, will publish its results for the second quarter and first half 2021 on July 28, 2021 at 10:00pm CEST (4:00pm EDT).
MorphoSys' Management Board will host a conference call and webcast on July 29, 2021 at 2:00pm CEST (8:00am EDT) to present the second quarter and first half financial results 2021 and provide a further outlook for 2021.
The conference call will start with a presentation by the Management Board followed by a Q&A session. Following Board Members will be on the call:
- Jean-Paul Kress, M.D., Chief Executive Officer
- Sung Lee, Chief Financial Officer
- Roland Wandeler, Ph.D., Chief Operating Officer
- Malte Peters, M.D., Chief Research & Development Officer
A live webcast and slides will be made available at the Media and Investors section under Conferences on MorphoSys' website, www.morphosys.com .
Dial-in number for the conference call (2:00pm CEST, 8:00am EDT):
Germany: +49 69 201 744 220
For UK residents: +44 203 009 2470
For US residents: +1 877 423 0830
(all numbers reachable from any geography)
Participant PIN: 72989449#
Please dial in 10 minutes before the beginning of the conference.
A replay of the conference will also be available at the corporate website following the live event.
About MorphoSys
MorphoSys (FSE:MOR)(NASDAQ:MOR) is a biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for people living with cancer and autoimmune diseases. Based on its leading expertise in antibody and protein technologies, MorphoSys is advancing its own pipeline of new drug candidates and has created antibodies that are developed by partners in different areas of unmet medical need. In 2017, Tremfya (R) (guselkumab) - developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc. for the treatment of plaque psoriasis - became the first drug based on MorphoSys' antibody technology to receive regulatory approval. In July 2020, the U.S. Food and Drug Administration granted accelerated approval of the company's proprietary product Monjuvi (R) (tafasitamab-cxix) in combination with lenalidomide for patients with a certain type of lymphoma. Headquartered near Munich, Germany, the MorphoSys Group, including the fully owned U.S. subsidiaries MorphoSys US Inc. and Constellation Pharmaceuticals, Inc., has more than 750 employees. For more information visit www.morphosys.com or www.morphosys-us.com .
Monjuvi (R) is a registered trademark of MorphoSys AG.
Tremfya (R) is a registered trademark of Janssen Biotech, Inc.
Forward Looking Statements
This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve known and unknown risks and uncertainties, which might cause the actual results, financial condition and liquidity, performance or achievements of MorphoSys, or industry results, to be materially different from any historic or future results, financial conditions and liquidity, performance or achievements expressed or implied by such forward-looking statements. In addition, even if MorphoSys' results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Among the factors that may result in differences are that MorphoSys' expectations may be incorrect, the inherent uncertainties associated with competitive developments, clinical trial and product development activities and regulatory approval requirements, MorphoSys' reliance on collaborations with third parties, estimating the commercial potential of its development programs and other risks indicated in the risk factors included in MorphoSys' Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. MorphoSys expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements, unless specifically required by law or regulation.
For more information, please contact:
Media Contacts:
Thomas Biegi
Vice President
Tel.: +49 (0)89 / 899 27 26 079
thomas.biegi@morphosys.com
Investor Contacts:
Dr. Julia Neugebauer
Senior Director
Tel: +49 (0)89 / 899 27 179
julia.neugebauer@morphosys.com
Jeanette Bressi
Director, US Communications
Tel: +1 617 404 7816
jeanette.bressi@morphosys.com
Myles Clouston
Senior Director
Tel: +1 857 772 0240
myles.clouston@morphosys.com
SOURCE: MorphoSys AG
View source version on accesswire.com:
https://www.accesswire.com/656539/Invitation-to-MorphoSys-Second-Quarter-and-First-Half-2021-Results-Conference-Call-on-July-29-2021
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Karbon-X Reports Increased Engagement as Canadian Facilities Reassess Compliance Exposure Ahead of Carbon Deadlines6.5.2026 15:15:00 CEST | Press release
170% year-over-year increase in traded volumes across TIER and BC OBPS within Karbon-X's trading activity reflects accelerated procurement activity as regulated entities enter the execution phase of the 2026 compliance cycle. CALGARY, AB / ACCESS Newswire / May 6, 2026 / Karbon-X Corp. (OTCQX:KARX) ("Karbon-X" or the "Company"), a vertically integrated climate solutions provider operating across compliance and voluntary carbon markets, today reported increased engagement from regulated facilities across Canada as organizations reassess their compliance position ahead of upcoming reporting and credit surrender deadlines. This includes a 170% increase in traded volumes across TIER and BC OBPS markets within Karbon-X's trading activity compared to the prior year, reflecting increased participation as facilities move into active procurement and execution phases ahead of submission timelines. As the current compliance cycle progresses across Alberta's Technology Innovation and Emissions Red
Global Sports Brand U.S. Polo Assn. Delivers Record $2.7 Billion in Retail Sales for 2025, Targets $4 Billion and 1,500 U.S. Polo Assn. Stores6.5.2026 13:00:00 CEST | Press release
WEST PALM BEACH, FL / ACCESS Newswire / May 6, 2026 / USPA Global, the company that manages U.S. Polo Assn., the official sports brand of the United States Polo Association (USPA), today announced that the global sports brand has delivered a record $2.7 billion in worldwide retail sales in 2025, reflecting strong momentum across global markets, channels, and product categories. U.S. Polo Assn. is advancing toward a long‑term goal of $4 billion in global retail sales and 1,500 branded stores worldwide. Record Growth and Global Momentum U.S. Polo Assn.'s 2025 record-breaking performance was driven by continued expansion across both established and emerging markets. North America, the brand's largest region, delivered steady gains, while strong momentum continued across India, the Middle East, Western Europe, and Latin America. Emerging regions, including Asia Pacific and Eastern Europe, also contributed to meaningful growth for the global multi-billion-dollar brand. India remains the bra
Case IQ Advances Its Leadership Position in AI For Investigations with Playbooks6.5.2026 10:00:00 CEST | Press release
Playbooks is a new way to guide AI toward investigative outcomes that ethics, compliance, and HR teams across the EU can trust. LONDON, GB / ACCESS Newswire / May 6, 2026 / Case IQ, the leading provider of end-to-end compliance and risk management solutions for ethics, compliance and HR teams, today announced Playbooks, a new enhancement to Clairia, its AI assistant purpose-built for investigators. Case IQ continues to raise the bar for AI in investigations with Playbooks, which brings greater consistency, control, and confidence to AI-assisted case management. Playbooks enable organizations to shape how AI supports investigators based on their own standards, policies, and operational needs. Organizations feel pressure to adopt AI for investigations, making it difficult to govern, especially while navigating different regulations and standards across EU regions/countries. It's no surprise, as AI adoption is rising: according to our recent investigative benchmark report, which surveyed
Transoft Solutions Acquires CADaptor Solutions6.5.2026 08:00:00 CEST | Press release
Transoft Solutions Expands Temporary Traffic Management Portfolio With Latest Acquisition VANCOUVER, BC / ACCESS Newswire / May 6, 2026 / Transoft Solutions, a global leader in transportation engineering, analysis, and operations software, is pleased to announce that it has acquired CADaptor Solutions Ltd, developers of temporary traffic management software. CADaptor Solutions is based out of Huddersfield, UK and was established over 30 years ago. Their CONE Software solution is used widely in the United Kingdom within the Traffic Management industry to aid in the preparation of temporary traffic control diagrams, route diversion and event management schemes. CONE covers all aspects of temporary traffic management design from simple pedestrian footways through to complex multi-lane highway closures and contra-flows. It is used by wide variety of traffic planning related professionals including Highways Agencies, Utility Companies, Local Government, Traffic Management Companies, Civil E
Lawline Exits Beta and Launches Full AI Legal Platform for Businesses and Individuals5.5.2026 15:00:00 CEST | Press release
Sweden's most visited legal platform, recognised among the Nordics' top 9 AI legal startups alongside Legora and others, moves out of beta after surpassing 7,000 registered users, expanding its offering for companies, organisations, and individuals. STOCKHOLM, SE / ACCESS Newswire / May 5, 2026 / Lawline, Sweden's most visited legal platform, today announced the official launch of its AI-driven legal platform, marking its transition out of beta. The launch introduces a significantly expanded product offering aimed at businesses, organisations, and individuals seeking accessible, reliable legal support in everyday decision-making. Lawline AI was first released in beta in February 2026 and has since attracted more than 7,000 registered users. With today's full launch, Lawline introduces a broader suite of capabilities designed to bring legal support closer to where decisions are actually made. "Legal support has traditionally been something you access after the fact, often when problems
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom